CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.1%

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) fell 1.1% during trading on Tuesday . The stock traded as low as $57.14 and last traded at $58.07. 375,745 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 1,842,429 shares. The stock had previously closed at $58.72.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Wolfe Research assumed coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. Chardan Capital raised their target price on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Mizuho boosted their price target on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Finally, Morgan Stanley raised their price objective on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $74.93.

CRISPR Therapeutics Stock Down 0.5 %

The company’s 50-day moving average price is $73.89 and its 200-day moving average price is $63.30. The firm has a market cap of $4.96 billion, a price-to-earnings ratio of -29.71 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. During the same quarter last year, the firm posted ($1.41) earnings per share. CRISPR Therapeutics’s quarterly revenue was up 3253.3% on a year-over-year basis. Analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 50,000 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the transaction, the chief executive officer now directly owns 187,377 shares in the company, valued at approximately $11,338,182.27. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 114,410 shares of company stock worth $7,984,677. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently made changes to their positions in the company. CWM LLC raised its position in CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after purchasing an additional 260 shares in the last quarter. Tradewinds Capital Management LLC grew its holdings in CRISPR Therapeutics by 545.5% during the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after acquiring an additional 600 shares in the last quarter. Blue Trust Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $32,000. Headlands Technologies LLC purchased a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth $34,000. Finally, Bourgeon Capital Management LLC grew its stake in shares of CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.